Patents by Inventor Julie Pannequin
Julie Pannequin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220195035Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: ApplicationFiled: March 7, 2022Publication date: June 23, 2022Applicants: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
-
Patent number: 11299542Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: GrantFiled: June 28, 2019Date of Patent: April 12, 2022Assignees: Les Laboratories Servier, Institut National de Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifiaue (CNRS)Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
-
Publication number: 20200002413Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: ApplicationFiled: June 28, 2019Publication date: January 2, 2020Applicants: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
-
Patent number: 10385125Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: GrantFiled: March 6, 2017Date of Patent: August 20, 2019Assignees: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
-
Patent number: 10385124Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: GrantFiled: March 6, 2017Date of Patent: August 20, 2019Assignees: Les Laboratoires Servier, Institut National de la Santè, Centre National de la Recherche Scientifique (CNRS)Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
-
Patent number: 10385126Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: GrantFiled: March 6, 2017Date of Patent: August 20, 2019Assignees: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
-
Patent number: 10377821Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: GrantFiled: March 6, 2017Date of Patent: August 13, 2019Assignees: Les Laboratoires Servier, Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)Inventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
-
Publication number: 20180022802Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: ApplicationFiled: March 6, 2017Publication date: January 25, 2018Inventors: Julie PANNEQUIN, Laure Boudier, Dominique Joubert, Frédéric Hollande
-
Publication number: 20170306012Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: ApplicationFiled: March 6, 2017Publication date: October 26, 2017Inventors: Julie PANNEQUIN, Laure Boudier, Dominique Joubert, Frédéric Hollande
-
Publication number: 20170306011Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: ApplicationFiled: March 6, 2017Publication date: October 26, 2017Inventors: Julie PANNEQUIN, Laure Boudier, Dominique Joubert, Frédéric Hollande
-
Publication number: 20170174761Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: ApplicationFiled: March 6, 2017Publication date: June 22, 2017Inventors: Julie PANNEQUIN, Laure BOU DIER, Dominique JOUBERT, Frédéric HOLLANDE
-
Patent number: 9611320Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: GrantFiled: October 15, 2010Date of Patent: April 4, 2017Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIQUE (CNRS), LES LABORATOIRES SERVIERInventors: Julie Pannequin, Laure Boudier, Dominique Joubert, Frédéric Hollande
-
Patent number: 9217032Abstract: The present disclosure is directed to methods of treating and preventing colorectal cancer metastasis or recurrence of colorectal cancer with compositions comprising anti-progastrin antibodies.Type: GrantFiled: January 4, 2011Date of Patent: December 22, 2015Assignee: LES LABORATOIRES SERVIERInventors: Julie Pannequin, Leïla Houhou, Bérénice Framery, Nejla Erkilic, Dominique Joubert, Frédéric Hollande
-
Publication number: 20110177063Abstract: The present disclosure is directed to methods of treating and preventing colorectal cancer metastasis or recurrence of colorectal cancer with compositions comprising anti-progastrin antibodies.Type: ApplicationFiled: January 4, 2011Publication date: July 21, 2011Applicants: BIOREALITES, S.A.S., INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Julie Pannequin, Leïla Houhou, Bérénice Framery, Nejla Erkilic, Dominique Joubert, Frédéric Hollande
-
Publication number: 20110117086Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: ApplicationFiled: October 15, 2010Publication date: May 19, 2011Applicants: BIORÉALITÉS S.A.S., INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: JULIE PANNEQUIN, LAURE BOUDIER, DOMINIQUE JOUBERT, FRÉDÉRIC HOLLANDE
-
Publication number: 20100209426Abstract: The present invention relates to inhibitors of progastrin induced repression of ICAT for treating and/or preventing colorectal cancer, adenomatous polyposis or metastasis displaying progastrin-secreting cells and cells in which the beta-catenin/Tcf-4-mediated transcriptional pathway is constitutively active.Type: ApplicationFiled: May 21, 2007Publication date: August 19, 2010Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC HERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERECHE SCIENTIFIQUE- CNRS, UNIVERSITE DE MONTPELLIER 1Inventors: Frederic Hollande, Dominique Joubert, Philippe Jay, Julie Pannequin, Nathalie Delaunay, Jean-Francois Bourgaux
-
Publication number: 20070031511Abstract: This invention relates to methods and compositions for the treatment of conditions associated with abnormal activity or secretion of the hormone gastrin. In particular the invention relates to the treatment of conditions associated with non-amidated gastrin. In one aspect there is provided a method of treatment or prophylaxis of a condition associated with elevated levels of non-amidated gastrin, comprising the step of administering to a mammal in need of such treatment an effective amount of a compound which has the ability to inhibit the binding of ferric ions to any one or more of glycine-extended gastrin17 or progastrin or progastrin-derived peptides, but which does not inhibit the activity of amidated gastrin, thereby to inhibit the activity of non-amidated gastrins.Type: ApplicationFiled: April 8, 2004Publication date: February 8, 2007Inventors: Graham Baldwin, Kevin Barnham, Julie Pannequin, John-Paul Tantiongco, Arthur Shulkes, Raymond Norton, Suzana Kovak, Hong He, Brian Sheehan